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ObesityThe combination of the obesity epidemic and an aging population presents growing challenges for the healthcare
system. Obesity and aging aremajor risk factors for a diverse number of diseases and it is of importance to under-
stand their interaction and the underlyingmolecularmechanisms. Herein the authors examined themethylation
levels of 27578 CpG sites in 46 samples from adult peripheral blood. The effect of obesity and aging was
ascertained with general linear models. More than one hundred probes were correlated to aging, nine of
which belonged to the KEGG group map04080. Additionally, 10 CpG sites had diverse methylation proﬁles in
obese and lean individuals, one of which was the telomerase catalytic subunit (TERT). In eight of ten cases the
methylation change was reverted between obese and lean individuals. One region proved to be differentially
methylated with obesity (LINC00304) independent of age. This study provides evidence that obesity inﬂuences
age driven epigenetic changes, which provides a molecular link between aging and obesity. This link and the
identiﬁed markers may prove to be valuable biomarkers for the understanding of the molecular basis of aging,
obesity and associated diseases.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Obesity and its associated co-disorders are some of the largest global
health problems andare togetherwith the increasing elderly population
in manywestern countries a major challenge for the healthcare system.
The risk for several age related diseases such as cancer, type-2 diabetes
and neurodegenerative diseases is increased by obesity and overweight
(Beydoun et al., 2008; Calle et al., 2003; Haslam and James, 2005).
Hence, it is of utmost importance to understand the mechanisms that
underlie these connections and the development of obesity and age relat-
ed diseases. Recent progress in genetic research has revealed a growing
number of genetic variants that predispose carriers to age related dis-
eases, in particular cancers (Hindorff et al., 2009). However, in the last
few years epigenetic alterations have been given an increasing amount
of attention as important factors in disease (Feinberg and Irizarry,
2010). In contrast to genetic variations, the epigenetic proﬁle is dynamic
and varies with both intrinsic and extrinsic factors throughout lifetime.d Genomes; Go-term, gene on-
G, CG sequence motif; LGDB,
rests.
).
. This is an open access article underEpigenetics covers a number of cellular mechanisms that alter the infor-
mation and interpretation of the genomewithout changing its nucleotide
sequence in contrast to classic genetic variations. One of themost studied
epigenetic mechanisms is the methylation of cytosine residues, which
is maintained and controlled by different DNA-methyltransferases
(DNMTs). Cytosines across the genome tend to be methylated (Ehrlich
et al., 1982), but in cytosine phosphate guanine (CpG) rich regions in
proximity of genes the methylation is dynamic and functions as a gene
speciﬁc regulatorymechanismof transcription (Bird et al., 1985). Such cy-
tosine enriched regions are called CpG islands and ahighermethylation in
this type of region is often associated with a reduced expression of the
nearby gene, due to chromatin rearrangement, inhibition of transcription
activators and/or recruitment of transcription repressors (Campion et al.,
2009; Mohn et al., 2008; Stein et al., 1982). Hence, DNAmethylation pro-
vides a regulatory mechanism of gene transcription and is essential for
cell fate, differentiation and tissue integrity.
The methylation status of monozygotic twins diverges with age,
which demonstrates that DNA methylation is susceptible to environ-
mental factors (Fraga et al., 2005). This strengthens the notion that
the epigenome is an adaptive entity capable of changing an individual's
gene expression pattern due to environmental factors. In fact, it has
been demonstrated that factors such as diet and nutrient intake affect
the methylation status as well as conditions such as inﬂammation, oxi-
dative stress and hypoxia (Campion et al., 2009). Several studies havethe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Description of the participants in the obese and lean group.
Obese Lean
N 24 22
Age (years)a 57 (42–70) 55 (41–69)
Weight (kg)a 92 (78–108) 60 (40–75)
BMI (kg/m2)a 35 (30–42) 22 (16–25)
a The values are given as the average and the range in parentheses.
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in obese individuals and varies with body-weight (Almen et al., 2012;
Franks and Ling, 2010; Milagro et al., 2011; Wang et al., 2010). In con-
trast, methylation levels are also associated with genetic variations
and can thus be governed, at least in part, by genetic factors
(Heijmans et al., 2007). This is exempliﬁed by a genome-wide longitu-
dinal study of DNAmethylation in an Icelandic population that conﬁrms
that inter-individual variation inmethylation level depends on both ge-
netic and environmental factors and that the extent of their inﬂuence
differs between regions (Bjornsson et al., 2008). We have previously
demonstrated that the obesity associated SNP rs9939609 in the FTO
gene is linked tomethylation changes in several CpG regions in preado-
lescents (Almen et al., 2012). FTO was the ﬁrst gene to be associated
with common obesity (Frayling et al., 2007).
With age the globalmethylation level of the genome (including non-
CpG regions) is decreased, which leads to a global hypomethylation
(Wilson and Jones, 1983; Wilson et al., 1987). This may be caused by a
lower expression of DNMT1 with age, which would lead to a slower
de novo and maintenance of methylation. In contrast, several CpG
islands in promoter regions are hypermethylated during aging (Kim
et al., 2004; Toyota et al., 1999; Tra et al., 2002). While this demon-
strates that the genome can be locally hypermethylated during aging,
it is unclear if this is a general process for promoter associated CpG
islands. These age associated methylation changes could be important
in age driven diseases and has received particular attention for its poten-
tial important role in cancer (Rando, 2010).Whereas it is well established
that genetic factors inﬂuence age related diseases, it is now clear that
epigenetic factors also play an important role (Liu et al., 2003).
In order to investigate the relation betweenmethylation status, obe-
sity and age we collected peripheral blood samples from 46 individuals
and analyzed their methylation proﬁles. DNA methylation levels were
measured with microarrays in 27,578 genomic sites, of which the ma-
jority were found in CpG islands in proximity of promoters. Moreover,
the inﬂuence of the obesity associated FTO genotype (rs9939609),
which lies in intron one and is not likely to have any cis effects on the
methylation, level was assessed in order to replicate our previous re-
sults. Blood samples provide the best way to locate potential diagnostic
biomarkers due to the simplicity of the clinical procedures involved. Im-
portantly, it is known that epigenetic changes identiﬁed in bloodmay be
representative for other tissues and can therefore be valuable as diag-
nostic and prognostic biomarkers (Calabrese et al., 2011).
2. Methods
2.1. Ethics statement
Written conﬁrmed consent was acquired from all participants of the
study. The studywas approved by theCentralMedical Ethics Committee
of Latvia.
2.2. Subjects
Study samples were acquired from the Latvian Genome Data Base
(LGDB), a national biobank of health and genetic information collected
for adult residents of Latvia (over 18 years old). Health status of thepar-
ticipants was asserted by health care professionals according to Interna-
tional Classiﬁcation of Diseases (ICD-10) codes. Information on a
familial health status, ethnic and social background, lifestyle and an-
thropometric measurements were obtained in a questionnaire based
interview.
We selected 24 obese and 22 lean female adults from a total group
of 934 females, with a known FTO rs9939609 genotype, that
were recruited to LGDB from 2003 to May 2009. Selection criteria in-
cluded rs9939609 genotype, Body Mass Index (BMI) (lean b25 kg/m2
and obese ≥30 kg/m2) and health status (participants diagnosed with
endocrine diseases and malignant tumors before recruiting to LGDBwere not included). Middle age females were selected and a com-
parable age range of the lean (41–69 years old) and obese females
(42–70 years old) were ascertained. The individuals were selected so
that both the obese and lean groups were composed of equal propor-
tions of homozygous carriers for the normal and risk allele of the
rs9939609 SNP. Heterozygous individuals were excluded. Age weight
and BMI details of the participants can be found in Table 1.
2.3. Illumina bead array
DNA isolationwas performed aswe have previously described using
the phenol chloroformmethod (Jacobsson et al., 2008). Bisulﬁte conver-
sionwas performedwith the EZDNAMethylation-Gold™ kit (Zymo Re-
search): 500 ng of DNA was subjected to bisulﬁte treatment including
heating to 98 °C for 10 min followed by conversion at 64 °C for
150min. The bisulﬁte conversion converts all (N99%) unmethylated cyto-
sine to uracil, which gives rise to a DNA sequence that can be deﬁned by
its initialmethylation status. The Illumina InﬁniumHumanMethylation27
BeadChip array (Illumina) probes 27,578 different CpG sites across the
whole genome and has been shown to yield reproducible results in
agreement with technologies such as bisulﬁte sequencing (Bibikova
et al., 2009). The BeadChip is designed by themanufacturer to preferen-
tially target CpG sites in proximity to the promoter of 14,475 genes of
the consensus coding sequences (CCDS) and known cancer genes as
well as the promoter of 110 miRNA promoters. Hence, the array is de-
signed to study CpG sites in proximity to genes and not themethylation
of intergenic cytosines or repeat regions. Chip design allowed for 12
samples to be processed on the same chip. The DNA was whole-
genome ampliﬁed, enzymatically fragmented, precipitated, and resus-
pended and after hybridization overnight at 48 °C the difference be-
tween a C or a T nucleotide was detected by single-base primer
extension. The ﬂuorescent detection was done using the Illumina
iScan scanner. Preprocessing of the ﬂuorescence signals and calculation
of the β-values, the ratio between the signal from the C and the sum of
the C and T signals, was performed with the GenomeStudio 2009.2
(Illumina) software. Probes that exhibited low quality (detection p-
value N0.01) were discarded from the set. The array data have been de-
posited at the Gene Expression Omnibus under accession GSE44763.
3. Statistics
The collection of site speciﬁc β-values was analyzed using the statis-
tical software R (www.r-project.org) in conjunctionwith themethylumi
and limma packages (Gentleman et al., 2004; Smyth, 2004). Beta values
are values ranging from zero to one corresponding to zero and 100%
methylation. Downstream analysis was made using the entire dataset
(excluding only high detection p-values). General linear models were
ﬁtted for each methylation value with the lmFit command using its
robust setting to minimize the inﬂuence of deviant samples, with
maximum iterations set to 1000. The empirical Bayes model imple-
mented in the limma package (eBayes command) was used to create
moderated t-statistics. p-Values were adjusted for multiple testing
using the Bonferroni method and the Benjamini–Hochberg method
(Benjamini et al., 2001). Probes that displayed an adjusted p-value of
more than 0.05 were considered non-signiﬁcant. In addition to p-
Table 2
Genes in proximity to sites where the methylation level changes with age dependent on
weight status (obese or lean). Each probe is listed along with the other probes that are
annotated to the same gene.
Gene 
symbol
Location Illumina ID Avg.  % Control
%/10 yearsa
Obese
%/10 yearsa
p–valueb Q–valuec
RNH1 Chr11:497970 cg06417962 83.95 –2.36 0.69 0.018 0.0042
Chr11:496809 cg15796682 5.83 0.86 0.31 0.368
ADCY1 Chr7:45581245 cg06417962 13.41 3.35 –0.64 0.018 0.0042
Chr7:45580250 cg13523557 14.18 1.47 –0.97 0.006
NNAT Chr20:35582093 cg12862537 76.98 –1.35 2.42 0.028 0.0066
Chr20:35582535 cg22510412 63.32 –1.01 2.15 0.008
Chr20:35582869 cg21588305 79.27 –1.26 0.92 0.012
Chr20:35582608 cg18433380 68.39 –0.07 1.63 0.215
Chr20:35583164 cg23566503 66.6 –0.45 0.67 0.323
Chr20:35582274 cg22298088 68.08 –0.78 0.52 0.361
Chr20:35583475 cg10642330 72.48 –0.56 0.43 0.388
CXADR Chr21:17807964 cg03167275 10.05 1.88 –0.33 0.029 0.0069
Chr21:17805938 cg00744433 72.87 –1.35 0.8 0.172
KCNS2 Chr8:99509124 cg05373457 24.16 5.33 –1.13 0.029 0.0069
LMX1B Chr9:128415668 cg09660171 9.24 1.7 –0.7 0.029 0.0069
Chr9:128416725 cg18453621 10.54 1.58 –0.6 0.016
FNDC4 Chr2:27571213 cg17918501 10.46 3.56 –0.24 0.029 0.0069
Chr2:27571677 cg20369763 9.63 1.42 –0.24 0.027
NAT8L Chr4:2030017 cg25044651 9.94 1.85 –1.33 0.039 0.0093
Chr4:2031721 cg15489294 11.33 1.77 0.25 0.127
AQPEP Chr5:115326619 cg21269934 18.53 3.95 –0.33 0.039 0.0093
Chr5:115325752 cg08211091 24.68 1.78 –0.43 0.037
FBLIM1 Chr1:15958229 cg23002761 9.03 2.5 –1.15 0.044 0.01
Chr1:15957345 cg07846167 22.84 0.08 0.24 0.779
a— % refers to methylation level of the site where 0 means that no alleles are methylated
and 100 means that all alleles are methylated. %/10 years denotes the percentage change
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ing Q-values using the qvalue package in Bioconductor with default
settings. The Q-value is a measurement of the number of expected
false positive that is detected among all signiﬁcant tests for a certain
p-value level (Storey and Tibshirani, 2003). If any probe for a speciﬁc
gene was considered signiﬁcant, all other probes for that same gene
were also investigated. A nominal p-value b0.05 was considered signif-
icant for these adjacent probes. Each probe was investigated for poten-
tial interaction between age and weight group (obese and lean) using
general linear models. Probes that had a signiﬁcant interaction were
also analyzed within the obese and lean group separately to retrieve
the group speciﬁc effect of aging on the methylation level of the site.
Furthermore, the probes with no signiﬁcant interaction were analyzed
without the interaction term to detect the main effect of obesity and
age on themethylation level. The inﬂuence of the FTO rs9939609 geno-
type, which lies in intron one and is not likely to have any cis effects, on
the methylation pattern was investigated by implementing a linear
model controlled for age and weight group. The signiﬁcant genes were
analyzed for enrichment of function using the Consensus database
(Kamburov et al., 2009, 2011) with all the 14,446 genes represented
in the Illumina Inﬁnium HumanMethylation27 BeadChip array that
passed QC used as a background. Both KEGG (Kanehisa et al., 2004),
the Kyoto Encyclopedia of Genes and Genomes (which catalogs genes
based on the biological pathway they are involved in) and level 4 bio-
logical process GO terms (Ashburner et al., 2000) were used for enrich-
ment analysis.over ten years.
b— p-values in shaded rows refer to the interaction term between age and weight status
and are adjusted according to the Benjamini–Hochberg method. p-Values in un-shaded
rows are the nominal p-values of the probes that are annotated to the reported gene.
c— the Q-value is an estimation of the false discovery rate (FDR) for the unadjusted
p-value of a certain test.
Table 3
Genes in proximity to sites that display change in methylation with age.
MLNR Chr13:48692682 cg02620013 27.76 2.9 0.00004 7.44*10-6 
cg07935568
AGPAT4 Chr6:161615551 cg07074571 34.4 3.02 0.00130 8.61*10-5 
ATP8A2 Chr13:24941066 cg18236477 21.68 2.95 0.00140 8.61*10-5 
cg12111714
BRUNOL6 Chr15:70399179 cg21801378 10.64 2.06 0.00250 0.00011 
cg16778903
NHLRC1 Chr6:18230698 cg22736354 21.9 2.42 0.00350 0.00013 
cg00772000
SERHL Chr22:41226632 cg12078929 13.74 4.13 0.00540 0.00015 
cg03855656
HBQ1 Chr16:170341 cg07703401 14.54 2.28 0.00570 0.00015 
cg17714030
PIGC Chr1:170680235 cg08587864 42.22 −3.87 0.01300 0.00028 
cg11584111 7.94 0.29 0.33264
NAGS Chr17:39437481 cg00462994 11.93 1.36 0.01400 0.00028 
cg04032226
CECR6 Chr22:15982681 cg18137704 21.97 1.7 0.01900 0.00036 
cg12373771
HTR7 Chr10:92607142 cg06291867 17.41 2.38 0.02300 0.00038 
cg26332534
FOXE3 Chr1:47654901 cg18815943 11.31 2.31 0.03000 0.00043 
cg18983672
ZNF154 Chr19:62912306 cg21790626 10.71 2.07 0.03000 0.00043 
Chr13:48692127 
Chr13:24941472 
Chr15:70399621 
Chr6:18231028 
Chr22:41226049 
Chr16:169983 
Chr1:170679460 
Chr17:39437918 
Chr22:15981381 
Chr10:92608043 
Chr1:47653843 
Chr19:62912474 cg08668790
16.85 0.84 0.01858
36.72 1.18 0.08145
4.45 0.26 0.17883
19.02 0.51 0.32754
42.93 0.32 0.75337
80.2 −1.45 0.07096
10.96 1.76 0.00247
12.57 1.06 0.05924
15.56 1.15 0.09341
69.48 -1.54 0.08635
14.22 3.06 0.00000
Gene 
symbol
Location Illumina ID Avg. %a %/10 yearsa p–valueb Q–valuec
a— % refers to methylation level of the site where 0 means that no alleles are methylated
and 100 means that all alleles are methylated. %/10 years denotes the percentage change
over ten years.
b — p-values in shaded rows are adjusted for multiple tests using Bonferroni correc-
tion. p-Values in un-shaded rows are the nominal p-values of the probes that are an-
notated to the reported gene.
c— the Q-value is an estimation of the false discovery rate (FDR) for the unadjusted
p-value of a certain test.4. Results
We wanted to ascertain whether age, obesity and their interaction
could predict the methylation status of speciﬁc CpG sites using an
array that predominantly targets regions in proximity of promoters.
We also sought to replicate our previous ﬁndings that a genetic varia-
tion within the FTO gene is associated with methylation changes. A lin-
ear model was implemented where the methylation of each site was
evaluated as a linear function of obesity, age and their interaction
term. In the case of the age associated genes, statistical analysis using
ConsensusPathDB was used to identify enriched functional clusters
among the differentially methylated genes.
A signiﬁcant correlation between age and methylation levels after
Benjamini–Hochberg correction (FDR b 0.01) was observed in 125
probes (Supplementary Table 1) of which 13 also proved signiﬁcant
under Bonferroni correction (Table 3). 70 of these 125 probes were
annotated to genes that had multiple probes associated to age with a
nominal p-value b0.05. Of all 125 probes, 34 showed reduced methyla-
tion with age and 91 were hypermethylated. An enrichment analysis of
functional and biological terms revealed the KEGG pathway map04080
“Neuroactive ligand–interceptor interaction” to be enriched in this
dataset (FDR b 0.01). Nine (PTGDR, MTRN1A, PRLHR, HTR7, MLNR,
GRIA2, GRM1, GLRA1, THRB) of the members of this KEGG group were
found among our age related sites. We identiﬁed an additional 10 re-
gions after Benjamini–Hochberg correction (Table 2, FDR b 0.02)
where the methylation levels depended on the interaction between
obesity and age and analyzed them separately in the lean and obese
group (Fig. 1). In eight (ADCY1, CXADR, KCNS2, LMX1B, FNDC4,
NAT8L, AQPEP and FBLIM1) of the ten cases the obese subjects
displayed decreased methylation with age when compared to
their lean counterparts, whereas the opposite was true for the
remaining two sites (RNH1 and NNAT). The gene “Long intergenic non
coding RNA 304”-LINC00304 (Illumina ID: cg03819692, position
chr16:87753140, located 11 bp from the transcription start site)
displayed higher methylation (p = 0.0030, adjusted with Benjamini–
Hochberg, FDR b 0.001) in the obese individuals compared to the lean,
independent of age (Fig. 2a). No other genewas found to be differential-
ly methylated between obese and lean individuals. Furthermore, no
Fig. 1.Methylation changeswith age in obese and lean individuals. Regression lines for age dependentmethylation changes are analyzed and depicted separately in the obese (pink color)
and lean (blue color) groups for the 10genes that displayed an interaction between age andweight group in the statistical analysis.Methylation levelwasmeasured in beta-values (0–100)
and age in years.
64 M.S. Almén et al. / Gene 548 (2014) 61–67differential methylation level could be detected between the normal
and risk allele carriers of the FTO gene.
The average methylation level of all probes on the array was calcu-
lated. This value was ﬁtted to a linear model and investigated forcorrelation with age and obesity. A trend for the average genome-
wide methylation levels to increase (p = 0.10) with age was observed
(Fig. 2b). No differential globalmethylation level was detected between
the obese and lean individuals (p N 0.25). It is important to stress that
Fig. 2.Methylation change for LINC00304 in obese and lean (a) and regression for genome-wide average methylation changes with age (b). a. The gene LINC0040, which codes for an
ncRNA, was the only gene differentially methylated in obese and lean individuals independent of age (p = 0.0030, adjusted with Benjamini–Hochberg). b. The average genome-wide
methylation displays a trend (p= 0.10) to be increasedwith age. Thismeasurements aremainly calculated fromCpG sites in proximity of promoters and donot necessarily reﬂect changes
in intergenic regions.
65M.S. Almén et al. / Gene 548 (2014) 61–67the genome-wide averagemethylation does not reﬂect the globalmeth-
ylation, which includes intergenic sites that are underrepresented on
the array.
5. Discussion
In this study we determined that 135 genomic sites are subject to
differential methylation during aging and that this process is inﬂuenced
by weight in a subset of loci, and that genes involved in neuroactive, li-
gand–receptor interaction are overrepresented among the 125 age-
related probes. In both tests, we identiﬁed several genes with multiple
signiﬁcant probes. We identiﬁed 10 sites with an interaction effect be-
tween obesity and aging. 8 of the sites had an interaction effect, i.e., a
higher level of hypermethylation during aging in lean individuals, com-
pared to obese individuals (Table 2 and Fig. 1). In contrast, the remain-
ing two sites were hypermethylated with aging in the obese group
compared to lean individuals. Hence, DNA methylation is a potential
molecular link between obesity and age related diseases, although the
mechanisms of this connection remain unclear. A possible explanation
is the elevated inﬂammation status associated with obesity, which is
tightly connected with adipokines and hormones that are secreted by
excessive adipose tissue and activated immune cells, which alter the
hormonal proﬁle of obese individuals (Hotamisligil, 2006). Another in-
teresting aspect is the beneﬁcial effect of caloric restriction, which is
known to prolong lifespan and protect against age related disorders
such as cancer, diabetes and cardiovascular disease in primates
(Colman et al., 2009). Restriction of energy intake has been reported
to induce elevated levels of DNMTs, which in turn is thought to increase
the methylation of genes that otherwise are upregulated during aging
and thought to be involved in cancer and other diseases (Chouliaras
et al., 2011). Hence, the different DNAmethylation patterns that we ob-
serve in obese and lean individuals during aging may be related to
higher energy intake in the obese group. Intriguingly, some of the de-
tected genes are known to be involved in age related diseases and obe-
sity: a genetic variation of the transcription factor LMX1B, which is
involved in the development and maintenance of dopaminergic neu-
rons, is associated with Parkinson's disease (Bergman et al., 2009); the
gene NNAT, is metabolically regulated in the hypothalamus through
leptin signaling and the locus is associated with obesity (Vrang et al.,
2010). The NNAT gene is also interesting because it is considered an
imprinted gene. Our results regarding this gene could reﬂect a differ-
ence at infancy between subjects. Thus, these 10 obesity-susceptible
genes are candidates for biomarkers that may improve the understand-
ing of how obesity affects the aging process and determine the underly-
ing molecular mechanisms between obesity and aging. Furthermore,
methylated sites associated with the genes CDKN2A, NPTX2, and
GRIA2 are associated with aging (Alves et al., 2013; Bocklandt et al.,2011; Koch andWagner, 2011; Liau et al., 2014). Although past studies
differ from ours in terms of analysis/samples/species, the detection of
the same genes is strong support of our results.
We found 125 sites that are differentially methylated during aging,
but not interacting with obesity. A majority (75%) of these sites
undergoes an increase in cytosine methylation with age, in conjunction
with previous reports (Kim et al., 2004; Toyota et al., 1999; Tra et al.,
2002). The age dependent genome-wide hypermethylation of
promoter associated CpG islands is also supported by the observed
trend (p= 0.10) of the average of all availablemarkers,which increases
with age (Fig. 2b). Hence, our results suggest that increasedmethylation
of CpG islands in proximity of genes during aging is a more common
process than hypomethylation, although our results also indicates that
most in proximity of genes sites are not affected by age. The design of
the array, which targets promoter associated CpG islands, does not
allow us to draw any conclusions on the global methylation pattern
that includes repeat regions and intergenic cytosines. The genes associ-
ated with the investigated sites where the DNA methylation was
hypermethylated by age include the telomerase catalytic subunit
(TERT, Supplementary information 1), which plays an important role
in aging, development and cancer. Also, TERT is known to be down reg-
ulated in lymphocytes during aging, which is in concert with our obser-
vation of increased methylation of the gene (Weng et al., 1996). Hence,
based on our results we speculate that DNAmethylation may be an im-
portant regulatory mechanism of TERT during aging and thereby indi-
rectly of telomere maintenance and cellular senescence. Several of the
other genes that are associatedwith age dependentmethylation chang-
es are relatedwith disorders that are known to be associatedwith aging.
The gene that was observed to have the strongest age dependentmeth-
ylation changes, MLNR, is a receptor for motilin. Interestingly, MLNR
regulates gastrointestinal activity and it is known that dysregulation of
this gene leads to constipation and diarrhea (Feighner et al., 1999).
The gene BRUNOL6/CELF6, which regulates the activity of troponin T
(TNNT2), is hypermethylated during aging and defects in TNNT2 regu-
lation are proposed to cause cardiomyopathy (Ladd et al., 2004). Disor-
ders related to bowel function and cardiovascular functions are known
to increase with age and the epigenetic links to these two genes may
provide insight into these processes. The serotonin receptor 7 (HTR7)
is suggested to be associated with late onset Alzheimer's disease (Liu
et al., 2007). Also, detection of differential methylation between obese
and lean individuals revealed a novel epigenetic marker that is in prox-
imity to the gene LINC00304 (Fig. 2a). Interestingly, LINC00304 is a long
intergenic non-protein coding RNA, amolecule type that often is associ-
ated with transcriptional regulation. However, the exact function of
LINC00304 is unknown. Albeit, it is unknown whether the observed
changes can be translated to other tissues, previous studies have
shown that DNA methylation changes measured in peripheral blood
66 M.S. Almén et al. / Gene 548 (2014) 61–67are, in several cases, disease speciﬁc for neurodegenerative diseases and
also bipolar disorder (Calabrese et al., 2011, Dempster et al., 2011). Dis-
ease and gene speciﬁc methylation in whole blood has also been shown
in Alzheimer's disease (Bollati et al., 2011). This suggests that epigenetic
alterations in blood cells can represent biomarkers for disorders speciﬁc
for other tissues.
A limitation of the study is the size and speciﬁcity of the sample.
Hence, the results cannot be generalized to a population level or to
other groups, such as children or individuals of advanced age.Moreover,
the relatively small changes reported here is cause for caution; technical
replicates in 5% of probes display a difference of 13.6% (Calabrese et al.,
2011) and the biggest change reported in this article is that of SERHL
which changes 4.13% every ten years adding up to a total of ~12%
change between the youngest and the oldest individuals. Peripheral
blood is an available biomaterial and therefore of clinical importance.
However, the use of peripheral blood may be a confounding factor as
the observed DNA methylation changes may reﬂect a systematic shift
in cell subpopulations with aging. Although changes in peripheral
blood have recently been shown to correlate well with that of different
brain regions (Horvath et al., 2012) we cannot be sure that this applies
for the genes reported here. Further studies that replicate ourﬁndings in
other groups and tissues and also investigate the function of the ob-
served DNA methylation changes are needed to ascertain the extent
and physiological role of our results. Although our results are generally
conﬁrmedbypast studies, the authors could not replicate theﬁndings in
regions reported by Heyn et al. (Heyn et al., 2012). Future studies with
larger sample sizes will likely detect differential methylation in sites
not reported here, due to limitations in statistical power. Nonetheless,
our estimated FDR b2% is a clear indication that the observed changes
in methylation are reliable.
Herein,we present evidence that obesity interfereswith age induced
epigenetic changes. Moreover, we have identiﬁed a large number of
genes that are susceptible to aging with respect to their DNA methyla-
tion proﬁle and a gene that is differentiallymethylated in obese individ-
uals. Although, the exact mechanisms behind the observed differences
remain unclear they emphasize that age has a large impact on epigenet-
ic programming and that this is inﬂuenced by lifestyle factors, which
may have great implications for the understanding of age and lifestyle
diseases.
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